Wall Street analyst estimates for Heartflow, Inc. Common Stock (HTFL): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart.
Consensus price target
$48.86 (-17 % vs price $59.10)
between $37.00 and $64.00 · 9 targets published in the last quarter
Closing price, Oct 28
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $249M | $248M – $249M | $-0.41 | 5 |
| 2027E | $309M | $302M – $314M | $-0.27 | 5 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (−2 sell to +2 buy) | 0.83 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.10 | ||
| 2026-08-13 | $-0.07 | $-0.13 | +47.6% |
| 2026-05-14 | $-0.16 | $-0.19 | +14.7% |
| 2026-03-18 | $-0.12 | $-0.19 | +36.0% |
| 2025-11-12 | $-0.27 | $-0.20 | -35.0% |
| 2025-09-19 | $-0.06 | $-0.21 | +71.8% |
| 2025-07-17 | $-0.46 | $-0.21 | -116.0% |
Valuation Ratios
| Price / Book | 18.25 |
| EV / EBITDA | -47.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $87.2M | $125.8M | $176.0M |
| Cost of Revenue | $29.1M | $31.4M | $40.8M |
| Gross Profit | $58.1M | $94.4M | $135.2M |
| Research & Development | $35.9M | $43.5M | $64.9M |
| Selling, General & Admin | $95.1M | $112.2M | $134.3M |
| Operating Expenses | $131.0M | $155.7M | $199.3M |
| Operating Income | -$72.9M | -$61.2M | -$64.1M |
| EBITDA | -$62.8M | -$65.5M | -$93.1M |
| Interest Expense | $24.7M | $22.8M | $15.2M |
| Pre-tax Income | -$95.1M | -$96.4M | -$116.9M |
| Income Tax | $547,000 | $53,000 | -$76,000 |
| Net Income | -$95.7M | -$96.4M | -$116.8M |
| EPS | $-1.94 | $-1.53 | $-1.37 |
| EPS (Diluted) | $-1.94 | $-1.53 | $-1.37 |
| Shares Outstanding (Diluted) | 63.9 M | 63.1 M | 85.3 M |
Price
| Price | $59.10 (closing price, October 28, 2026) |
| Market Cap | $5.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: TEM · BTSG · HNGE · HQY · DOCS · WAY · PRVA
Explore sector: Healthcare · Medical - Healthcare Information Services
More sections of HTFL: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks